Ultragenyx Pharmaceutical Inc (RARE)
44.10
+1.82
(+4.32%)
USD |
NASDAQ |
Apr 17, 16:00
44.10
0.00 (0.00%)
After-Hours: 19:04
Ultragenyx Pharmaceutical Cash from Investing (TTM): 168.00M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 168.00M |
September 30, 2023 | 103.42M |
June 30, 2023 | -122.74M |
March 31, 2023 | -142.99M |
December 31, 2022 | -291.65M |
September 30, 2022 | -51.00M |
June 30, 2022 | 70.10M |
March 31, 2022 | -50.31M |
December 31, 2021 | -195.37M |
September 30, 2021 | -166.53M |
June 30, 2021 | -221.53M |
March 31, 2021 | -266.42M |
December 31, 2020 | -179.12M |
September 30, 2020 | -209.76M |
June 30, 2020 | -34.68M |
March 31, 2020 | -6.971M |
December 31, 2019 | -13.04M |
September 30, 2019 | -6.744M |
June 30, 2019 | -69.85M |
March 31, 2019 | -63.50M |
December 31, 2018 | -33.33M |
Date | Value |
---|---|
September 30, 2018 | -49.50M |
June 30, 2018 | -35.92M |
March 31, 2018 | -4.926M |
December 31, 2017 | 55.48M |
September 30, 2017 | -9.062M |
June 30, 2017 | 13.66M |
March 31, 2017 | 58.72M |
December 31, 2016 | 91.12M |
September 30, 2016 | 64.71M |
June 30, 2016 | -131.51M |
March 31, 2016 | -266.51M |
December 31, 2015 | -292.35M |
September 30, 2015 | -275.81M |
June 30, 2015 | -145.64M |
March 31, 2015 | -62.11M |
December 31, 2014 | -123.44M |
September 30, 2014 | -95.31M |
June 30, 2014 | -82.55M |
March 31, 2014 | -98.03M |
December 31, 2013 | -47.73M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-291.65M
Minimum
Dec 2022
168.00M
Maximum
Dec 2023
-88.80M
Average
-69.85M
Median
Jun 2019
Cash from Investing (TTM) Benchmarks
Corcept Therapeutics Inc | 90.91M |
Madrigal Pharmaceuticals Inc | -502.52M |
Sarepta Therapeutics Inc | -165.80M |
Rocket Pharmaceuticals Inc | -98.07M |
Apellis Pharmaceuticals Inc | -0.674M |